Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hepatitis C

The role of new interferons in the era of STAT-C

Nature Reviews Gastroenterology & Hepatology volume 6, pages 509–511 (2009)Cite this article

More than 50% of patients infected with HCV genotype 1 fail respond to standard treatment with peginterferon plus ribavirin. Potent treatment strategies are urgently needed to improve outcomes for such patients. Novel interferons and specifically targeted antiviral therapy for HCV (STAT-C) represent promising strategies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Marcellin, P. Hepatitis B and hepatitis C in 2009. Liver Int. 29 (Suppl. 1), 1–8 (2009).

    Article  Google Scholar 

  2. Shiffman, M. L. et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126, 1015–1023 (2004).

    Article  CAS  Google Scholar 

  3. Moucari, R. et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J. Hepatol. 46, 596–604 (2007).

    Article  CAS  Google Scholar 

  4. Poynard, T. et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 136, 1618–1628 (2009).

    Article  CAS  Google Scholar 

  5. Moucari, R. et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134, 416–423 (2008).

    Article  CAS  Google Scholar 

  6. Di Bisceglie, A. M. et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 359, 2429–2441 (2008).

    Article  CAS  Google Scholar 

  7. Jensen, D. M. et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-α2b: a randomized trial. Ann. Intern. Med. 150, 528–540 (2009).

    Article  Google Scholar 

  8. Bacon, B. R. et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 49, 1838–1846 (2009).

    Article  CAS  Google Scholar 

  9. Leevy, C. B. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig. Dis. Sci. 53, 1961–1966 (2008).

    Article  CAS  Google Scholar 

  10. Neslon, D. R. et al. Sustained virologic response with albinterferon alfa-2b/ribavirin treatment in prior interferon therapy non-responders [abstract]. Hepatology 46 (Suppl. 1), 256A (2007).

    Google Scholar 

  11. Manns, M. et al. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon alfa-2a/b and ribavirin therapy: SVR results of the PROVE 3 study [abstract]. J. Hepatol. 50 (Suppl. 1), S379 (2009).

    Article  Google Scholar 

  12. Schiff, E. et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on Interferon responsiveness [abstract]. J. Hepatol. 48 (Suppl. 2), S46 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d'Hépatologie and INSERM U773, Hôpital Beaujon, Clichy, France

    Rami Moucari & Patrick Marcellin

Authors
  1. Rami Moucari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Marcellin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Marcellin.

Ethics declarations

Competing interests

P. Marcellin is a Consultant, a member of the Speaker's Bureau, and has received grant/research support from Bristol-Myers Squibb, Gilead, Novartis, Roche, Schering Plough, Tibotec and Vertex. R. Moucari declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moucari, R., Marcellin, P. The role of new interferons in the era of STAT-C. Nat Rev Gastroenterol Hepatol 6, 509–511 (2009). https://doi.org/10.1038/nrgastro.2009.141

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2009.141

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing